These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 1984470)

  • 1. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever.
    Kalman D; Barriere SL
    J Infect Dis; 1991 Jan; 163(1):201-3. PubMed ID: 1984470
    [No Abstract]   [Full Text] [Related]  

  • 2. [Infections in neutropenic patients].
    Berenguer J
    Enferm Infecc Microbiol Clin; 1995 Feb; 13(2):113-20. PubMed ID: 7711117
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever.
    Jun HX; Zhixiang S; Chun W; Reksodiputro AH; Ranuhardy D; Tamura K; Matsumoto T; Lee DG; Purushotaman SV; Lim V; Ahmed A; Hussain Y; Chua M; Ong A; Liu CY; Hsueh PR; Lin SF; Liu YC; Suwangool P; Jootar S; Picazo JJ
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S128-32; discussion S133-40. PubMed ID: 16253480
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevant aspects in the Infectious Diseases Society of America (IDSA) guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever.
    Zinner SH
    Int J Hematol; 1998 Oct; 68 Suppl 1():S31-4. PubMed ID: 9838742
    [No Abstract]   [Full Text] [Related]  

  • 6. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever.
    Hughes WT; Armstrong D; Bodey GP; Feld R; Mandell GL; Meyers JD; Pizzo PA; Schimpff SC; Shenep JL; Wade JC
    J Infect Dis; 1990 Mar; 161(3):381-96. PubMed ID: 2179420
    [No Abstract]   [Full Text] [Related]  

  • 7. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
    Klastersky J
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European experience of timentin in combination with aminoglycosides as empirical treatment in febrile neutropenic patients.
    Croydon E; Weerts D
    Chemioterapia; 1987 Jun; 6(2 Suppl):405-7. PubMed ID: 3334585
    [No Abstract]   [Full Text] [Related]  

  • 9. Empirical therapy of infections in neutropenic patients.
    Gaya H
    Br J Haematol; 1998 May; 101 Suppl 1():5-9. PubMed ID: 9607734
    [No Abstract]   [Full Text] [Related]  

  • 10. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why monotherapy?
    Williams KJ
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i18-20. PubMed ID: 19372175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years.
    Bodey GP
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i3-13. PubMed ID: 19372179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society).
    Link H; Böhme A; Cornely OA; Höffken K; Kellner O; Kern WV; Mahlberg R; Maschmeyer G; Nowrousian MR; Ostermann H; Ruhnke M; Sezer O; Schiel X; Wilhelm M; Auner HW; ;
    Ann Hematol; 2003 Oct; 82 Suppl 2():S105-17. PubMed ID: 13680173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empiric therapy for infections in the febrile, neutropenic, compromised host.
    Giamarellou H
    Med Clin North Am; 1995 May; 79(3):559-80. PubMed ID: 7752729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Where do we go from here?
    Pizzo PA
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i16-7. PubMed ID: 19372174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial therapy--special considerations in neutropenic patients.
    Rodriguez V; Bodey GP
    Clin Haematol; 1976 Jun; 5(2):347-60. PubMed ID: 181192
    [No Abstract]   [Full Text] [Related]  

  • 16. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Summary and comments.
    Sinkó J; Kullberg BJ; Edwards JE; Anaissie E
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i41-3. PubMed ID: 19372182
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of the febrile neutropenic patient.
    Picazo JJ;
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S120-2; discussion S133-40. PubMed ID: 16243492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antimicrobial therapy in neutropenia].
    Maschmeyer G; Vogt K; Hahn H; Dörken B
    Dtsch Med Wochenschr; 1997 Jul; 122(27):864-9. PubMed ID: 9280698
    [No Abstract]   [Full Text] [Related]  

  • 19. [Diagnostic procedures and management of Fever in pediatric cancer patients].
    Laws HJ; Ammann RA; Lehrnbecher T
    Klin Padiatr; 2005 Nov; 217 Suppl 1():S9-16. PubMed ID: 16288350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic antimicrobial agents and the importance of fitness.
    Baden LR
    N Engl J Med; 2005 Sep; 353(10):1052-4. PubMed ID: 16148291
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.